Abstract
Klebsiella pneumoniae producing KPC-type carbapenemase causes severe nosocomial infection at a high mortality rate. Nosocomial pneumonia in particular is associated with high mortality, likely due to the unfavorable pulmonary pharmacokinetics of the antibiotics used against this agent. Therefore, early and accurate microbiological identification and susceptibility evaluation are crucial in order to optimize antibiotic therapy. We report a case of ventilator-associated pneumonia caused by colistin-resistant K. pneumoniae producing KPC-type carbapenemase treat edusing a carbapenem-sparing therapy and tailored according to the serum procalciton in concentration in order to limit the duration of antibiotic therapy.
Keywords
Ventilator-associated pneumoniaColistin-resistant KPC producingKlebsiella pneumoniaeIntensive care unitDrug pharmacokinetics